Immunocore Holdings plc Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Immunocore Holdings plc (IMCR) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -57.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-08-06
- Immunocore Holdings plc effective income tax rate reconciliation, tax credit, percent for the quarter ending 2026-06-30 was -57.20%.
- Immunocore Holdings plc effective income tax rate reconciliation, tax credit, percent for the quarter ending 2026-03-31 was 2.30%, a 86.78% decline year-over-year.
- Immunocore Holdings plc effective income tax rate reconciliation, tax credit, percent for the quarter ending 2025-09-30 was 155.50%.
- Immunocore Holdings plc effective income tax rate reconciliation, tax credit, percent for the quarter ending 2025-06-30 was -6.30%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 9 month |
|---|---|---|---|
| 2026-06-30 | -57.20% 10-Q · filed 2026-08-06 | 4.70% 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 2.30% 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | 155.50% 10-Q · filed 2025-11-06 | -64.90% 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -6.30% 10-Q · filed 2025-08-07 | -46.10% 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 17.40% 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | 2.80% 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | -5.40% 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 1.50% 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |